Table 1.
Baseline demographics and disease characteristics
| RAS wild-type | RAS wild-type/BRAF wild-type | |||
|---|---|---|---|---|
| Panitumumab + mFOLFOX6 (n = 88) | Bevacizumab + mFOLFOX6 (n = 82) | Panitumumab + mFOLFOX6 (n = 77) | Bevacizumab + mFOLFOX6 (n = 79) | |
| Male sex, n (%) | 58 (66) | 56 (68) | 50 (65) | 55 (70) |
| Age, years – median (range) | 62 (23–82) | 60 (39–82) | 62 (23–82) | 60 (39–82) |
| ECOG PS, n (%) | ||||
| 0 or 1 | 88 (100) | 81 (99) | 77 (100) | 78 (99) |
| Missing | 0 (0) | 1 (1) | 0 (0) | 1 (1) |
| Primary tumour diagnosis, n (%) | ||||
| Colon | 64 (73) | 57 (70) | 53 (69) | 54 (68) |
| Rectum | 24 (27) | 25 (30) | 24 (31) | 25 (32) |
| Primary tumour location, n (%) | ||||
| Left | 53 (60) | 54 (66) | 52 (68) | 53 (67) |
| Right | 22 (25) | 14 (17) | 13 (17) | 13 (16) |
| Unknown/unavailable | 13 (15) | 14 (17) | 12 (16) | 13 (16) |
| Sites of metastases, n (%) | ||||
| Liver only | 23 (26) | 22 (27) | 21 (27) | 22 (28) |
| Liver + other | 43 (49) | 34 (41) | 37 (48) | 33 (42) |
| Other only | 22 (25) | 26 (32) | 19 (25) | 23 (29) |
| Number of metastatic sites, median (range) | 2 (1–5) | 2 (0–4) | 2 (1–5) | 2 (0–4) |
| Sum of longest diameters of all target lesions, mm – mean (standard deviation)a | 129.0 (117.2) | 109.1 (84.5) | 131.6 (123.5) | 110.2 (85.2) |
| CEA levels, μg/L – median (range) | 12.8 (0–8543) | 15.2 (1–4889) | 12.6 (0–8453) | 15.6 (1–4889) |
aSum of longest diameters of target lesions was missing/unknown for one patient in the bevacizumab group
CEA carcinoembryonic antigen, ECOG PS Eastern Cooperative Oncology Group performance status